Our #STOPCAP #IPDMA of #docetaxel for advanced #prostateCancer #mHSPC came out this week in #LancetOncology!

Very excited about this: result of tremendous collaborative effort to obtain harmonized trial data, apply meticulous checking & processing, and carry out high-quality statistical analysis. Aim was to clarify patterns of survival within patient subgroups most & least likely to benefit.

https://doi.org/10.1016/S1470-2045(23)00230-9

Finally: this paper had a long & difficult gestation - e.g. searching in 2020! No further summary-data #NMA will be done *in this field*; things have moved on. But our *conclusions* remain important. (Also, #IPDMA in advanced #ProstateCancer is ongoing - watch this space!) (5/5)

Love the idea of #Introduction posts!

Hi I'm David, a #statistician & #methodologist at #UCL, working in #ClinicalTrials and #MetaAnalysis (MA), particularly in #oncology & with #survival data. I've been involved in large-scale #RCTs, meta-analysis of #COVID19 data on behalf of #WHO, and currently working with large-scale #IPDMA in #prostateCancer. Main methodological interest is treatment interactions with observed patient #subgroups in MA. I also write & maintain #Stata packages.